United Therapeutics Officer Files Form 144 to Sell $101.8M in Common Stock
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 144 Filing Alert: UNITED THERAPEUTICS Corp ($UTHR) ⢠Insider: MARTINE ROTHBLATT (Officer) ⢠Proposed Sale: 199,500 shares of Common Stock ⢠Estimated Market Value: $101,820,810.00 (~$510.38/share) ⢠Acquisition Source: Stock Option Exercise (Cash payment, 09/01/2026) ⢠Broker: Morgan Stanley Smith Barney LLC ⢠Trading Plan: Executed under Rule 10b5-1 plan adopted on 11/21/2025
Comprehensive Analysis
Executive Summary
On September 1, 2026, Martine Rothblatt, an officer of United Therapeutics Corp ($UTHR), submitted a Form 144 notice of proposed sale for 199,500 shares of common stock with an aggregate market value of approximately $101.82 million.
Key Transaction Details
- Securities to be Sold: 199,500 Common Shares
- Aggregate Market Value: $101,820,810.00 (implied ~$510.38 per share)
- Nature of Acquisition: Exercise of stock options from the issuer against cash on September 1, 2026
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Plan Adoption: Conducted pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025
Historical Context & Market Impact
- Over the prior three months, regular daily sales of 9,500 shares have occurred in accordance with the established 10b5-1 trading schedule.
- Total shares outstanding for the issuer stand at 42,890,692, meaning the proposed sale represents roughly 0.47% of total outstanding shares.
- While the monetary magnitude is significant ($101.8M+), the programmatic nature and advance adoption of the 10b5-1 plan substantially mitigate unexpected negative signaling.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
